Johnson v. Strive East Harlem Emplyment Group et al, No. 1:2012cv04460 - Document 83 (S.D.N.Y. 2014) case opinion from the Southern District of New York US Federal District Court.
Aug 15, 2014 ... According to the Alabama Supreme Court, “Under Alabama law, a brand-name drug company may be held liable for fraud or misrepresentation (by misstatement or omission), based on statements it made in connection with the manufacture of a brand-name prescription drug, by a plaintiff claiming physical ...
Feb 22, 2011 ... prepared by the Reporter of Decisions for the convenience of the reader. See United States v. Detroit Timber & Lumber Co., 200 U. S. 321, 337. SUPREME COURT OF THE UNITED STATES. Syllabus. BRUESEWITZ ET AL. v. WYETH LLC, FKA WYETH, INC.,. ET AL. CERTIORARI TO THE UNITED STATES ...
United States Supreme Court. BRUESEWITZ ET AL. v. WYETH LLC, FKA WYETH, INC., ET AL., (2011). No. 09-152. Argued: October 12, 2010 Decided: February 22, 2011. The National Childhood Vaccine Injury Act of 1986 (NCVIA or Act) created a no-fault compensation program to stabilize a vaccine market adversely ...
Oct 12, 2010 ... Two hours after Hannah Bruesewitz received her six-month diphtheria, tetanus and pertussis vaccine in 1992, she started developing seizures and was hospitalized for weeks. Hannah has continued to suffer from residual seizure disorder that requires her to receive constant care, according to her parents.
Johnson & Johnson, et al., 2017 WL 6945335 (C.D. Ill. Sept. ... Inc., 793 N.E.2d 869, 874-76 (2003) (same) (all four cases finding no causation as a matter of law without product identification). ... Celotex Corp., 554 N.E.2d 468, 470-471 (Ill. App . 1990) (rejecting market share liability pre-Smith in asbestos case); York v.
Jul 9, 2015 ... Wyeth Laboratory Inc. in 1999 — holding that in direct to consumer marketing of pharmaceuticals the learned intermediary doctrine did not apply — no ... exception to the learned intermediary doctrine is inapplicable here.” Simineri, et al. v. LifeCell Corp., No. L-597211, Mem. Decision at n. 3 (N.J. Super.
Aug 16, 2016 ... JOHN J. MOLENDA, Steptoe & Johnson, LLP, New. York, NY, argued for ... APOTEX INC. v. WYETH LLC. 3 tion emerges as the “predominant degradation pathway.” See id. col. 2 ll. 45–50. Tigecycline and its epimer differ in one respect: “[i]n ... Publication No. 1390550A (“CN '550”); V. Naggar et al.,.
corporation did not purchase all or most of the assets of the predecessor). 10. ... and Perez v. Wyeth Laboratories, Inc. announced that pharmaceutical sellers may have a duty to warn patients directly, contrary to the no-duty learned ... See Frances E. Zollers et al., Looking Backward, Looking Forward: Reflections on Twenty.